Nasdaq

Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis

Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies “Mapi Pharma and Mylan share a commitment to improve the lives of MS patients, and I am ...

Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions

Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced that management will participate in the ...
Nasdaq

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...
Business Insider

Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables

NESS ZIONA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today ...
MarketWatch

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
manilatimes

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...